序号 |
标题 |
次数 |
作者 |
发布时间 |
74881 |
DOTA-VAP-1 螯合剂DOTA偶联VAP-1靶向肽 |
145 |
h |
2024-12-18 |
74882 |
DOTA-GIP-C803 DOTA螯合剂缀合GIPC803肽 |
72 |
h |
2024-12-18 |
74883 |
DOTA-mPS 螯合剂DOTA修饰微米级聚苯乙烯 |
104 |
h |
2024-12-18 |
74884 |
DOTA-HBED-bisphosphonate DOTA-HBED-二膦酸盐 |
100 |
h |
2024-12-18 |
74885 |
CAS号:2226472-28-0 ,DBCO-PEG4-Val-Cit-PAB-PNP |
104 |
WYQ |
2024-12-18 |
74886 |
cas:2112738-09-5, Mal-PEG4-Val-Cit-PAB-PNP |
116 |
WYQ |
2024-12-18 |
74887 |
Mal-PEG8-Val-Cit-PAB-PNP,可以溶解于DCM、DMF、DMSO、THF等有机溶剂,以及水中。 |
121 |
WYQ |
2024-12-18 |
74888 |
Mal-PEG2-Val-Ala-PAB-PNP,含有马来酰亚胺(Mal)官能团、两个单元的聚乙二醇(PEG2)间隔物、缬氨酸(Val)和丙氨酸(Ala)的序列 |
75 |
WYQ |
2024-12-18 |
74889 |
Mal-PEG2-Val-Cit-PABA(CAS号:1662687-83-3) |
94 |
WYQ |
2024-12-18 |
74890 |
CAS号:1096584-62-1, Mal-Val-Cit-PAB-PNP |
71 |
WYQ |
2024-12-18 |
74891 |
Mal-amido-PEG2-Val-Cit-PAB-OH,马来酰亚胺-酰胺-二聚乙二醇-缬氨酸-瓜氨酸-PAB-羟基 |
70 |
WYQ |
2024-12-18 |
74892 |
CAS号:1949793-41-2 ,Mal-amido-PEG4-Val-Cit-PAB-OH |
82 |
WYQ |
2024-12-18 |
74893 |
DOTA-伊班膦酸 DOTA-IBA |
75 |
h |
2024-12-18 |
74894 |
FA-DOTA-PEG-PLGA 叶酸-DOTA-聚乙二醇-聚乳酸-羟基乙酸共聚物 |
83 |
h |
2024-12-18 |
74895 |
DOTA-泛素29-41 |
74 |
h |
2024-12-18 |
74896 |
cas:1226403-39-9,N-(2-(3,4-Difluorophenoxy)ethyl)-4-formylbenzamide |
77 |
kx |
2024-12-18 |
74897 |
Cu-64 DOTA-曲妥珠单抗 Cu-64-Herceptin |
122 |
h |
2024-12-18 |
74898 |
CAS号:2112738-13-1 ,Mal-amido-PEG2-Val-Cit-PAB-PNP |
80 |
WYQ |
2024-12-18 |
74899 |
CAS号:2055041-40-0 , Azido-PEG1-Val-Cit-PAB-OH |
91 |
WYQ |
2024-12-18 |
74900 |
cas:1226006-55-8,N-(2-(3-Ethoxyphenoxy)ethyl)-4-formylbenzamide, ADC试剂 |
68 |
kx |
2024-12-18 |
74901 |
DOTA-LTVSPWY 双功能螯合剂DOTA偶联肽LTVSPWY |
74 |
h |
2024-12-18 |
74902 |
CAS号:2055024-65-0 ,Azido-PEG3-Val-Cit-PAB-OH |
79 |
WYQ |
2024-12-18 |
74903 |
DOTA-CCK-66 大环DOTA偶联CCK2R靶向化合物CCK-66 |
182 |
h |
2024-12-18 |
74904 |
cas:1228153-04-5,4-Formyl-N-(2-(naphthalen-2-yloxy)ethyl)benzamide |
105 |
kx |
2024-12-18 |
74905 |
抗DOTA IgG-scFv BsAb anti-DOTA IgG-scFv BsAb |
121 |
h |
2024-12-18 |
74906 |
cas:1226217-30-6,4-Formyl-N-(2-(4-isopropylphenoxy)ethyl)benzamide |
81 |
kx |
2024-12-18 |
74907 |
DOTA-rL-A9肽 DOTA偶联核定位序列(NLS)-移植的her 2-受体亲和肽 |
101 |
h |
2024-12-18 |
74908 |
cas:796073-59-1,2,5-Dioxopyrrolidin-1-yl 4-(methyldisulfanyl)pentanoate |
71 |
kx |
2024-12-18 |
74909 |
DOTA-E[c(RGDFK)]2 双功能螯合剂偶联的RGD多肽E[c(RGDfK)]2 |
76 |
h |
2024-12-18 |
74910 |
DBCO-C4-Val-Cit-PABC-PNP,分子式:C46H49N7O10 |
83 |
WYQ |
2024-12-18 |
74911 |
DBCO-(PEG)3-VC-PAB-MMAE,CAS号:57103-68-1 |
55 |
WYQ |
2024-12-18 |
74912 |
cas:1134280-65-1,2,5-Dioxopyrrolidin-1-yl 3-((2,4-difluorobenzyl)oxy)propanoate |
78 |
kx |
2024-12-18 |
74913 |
DBCO-PEG3-acetic-Val-Cit-PAB(二苯并环辛炔) |
84 |
WYQ |
2024-12-18 |
74914 |
cas:1824718-79-7,SPDH, ADC试剂 |
86 |
kx |
2024-12-18 |
74915 |
cas:1232769-29-7,2,5-dioxopyrrolidin-1-yl 19-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-19-oxo-4,7,10,13,16-pentaoxanonadecan-1-oate |
88 |
kx |
2024-12-18 |
74916 |
Amino-PEG2-VG-N-Bis(PEG1-azide),氨基-二聚乙二醇-VG-N-双(一聚乙二醇-叠氮) |
126 |
WYQ |
2024-12-18 |
74917 |
Alkyne-Val-Cit-PAB-FAM,炔-VAL-CIT-PAB-FAM |
73 |
WYQ |
2024-12-18 |
74918 |
cas:1226218-43-4,4-Formyl-N-(2-(2,3,6-trimethylphenoxy)ethyl)benzamide |
69 |
kx |
2024-12-18 |
74919 |
双功能螫合剂DOTA偶联MAG3 DOTA-MAG3 |
107 |
h |
2024-12-18 |
74920 |
Alkyne-Val-Cit-PAB-PNP,炔-Val-Cit-PAB-PNP |
86 |
WYQ |
2024-12-18 |
74921 |
DOTA-MSH2 金属螯合剂DOTA偶联二聚体肽(MSH2) |
94 |
h |
2024-12-18 |
74922 |
cas:796073-64-8,(S)-2,5-Dioxopyrrolidin-1-yl 4-(methyldisulfanyl)pentanoate |
71 |
kx |
2024-12-18 |
74923 |
N,N-二乙基正辛硫基乙酰胺,(N,N-Diethyl-α-(OctlyThio)-Acetamide)简称DOTA |
72 |
h |
2024-12-18 |
74924 |
cas:437655-95-3,Fmoc-NH-PEG4-CH2COOH, 5,8,11,14-四氧杂-2-氮杂十六碳二酸 1-芴甲基酯 |
82 |
kx |
2024-12-18 |
74925 |
Val-Ala-PAB-OH |
104 |
zyl |
2024-12-18 |